Skip to content

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Plaque Psoriasis

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice.

Risankizumab is an approved drug for treating participants with Psoriasis. Approximately 700 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 70 sites worldwide.

Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 2.5 years.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment.
* Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines.
* Decision to treat with risankizumab is made prior to and independently of study participation.

Exclusion Criteria:

* History of a sleep disorder diagnosis which the patient is currently being treated for.
* Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study.
* Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.

Lieu de l'étude

Winnipeg Clinic /ID# 276751
Winnipeg Clinic /ID# 276751
Winnipeg, Manitoba
Canada

Contactez l'équipe d'étude

Dermatrials Research /ID# 276714
Dermatrials Research /ID# 276714
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

JRB Research inc. /ID# 277730
JRB Research inc. /ID# 277730
Ottawa, Ontario
Canada

Contactez l'équipe d'étude

North York Research Inc /ID# 276835
North York Research Inc /ID# 276835
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Lynderm Research Inc /ID# 276755
Lynderm Research Inc /ID# 276755
Markham, Ontario
Canada

Contactez l'équipe d'étude

Cca Medical Research /ID# 276944
Cca Medical Research /ID# 276944
Ajax, Ontario
Canada

Contactez l'équipe d'étude

SKiN Centre for Dermatology /ID# 277594
SKiN Centre for Dermatology /ID# 277594
Peterborough, Ontario
Canada

Contactez l'équipe d'étude

Dre Angelique Gagne-Henley M.D. inc. /ID# 276687
Dre Angelique Gagne-Henley M.D. inc. /ID# 276687
Saint-Jérôme, Quebec
Canada

Contactez l'équipe d'étude

Quinte dermatology /ID# 277497
Quinte dermatology /ID# 277497
Belleville, Ontario
Canada

Contactez l'équipe d'étude

Rejuvenation Dermatology Clinic Oakville /ID# 277492
Rejuvenation Dermatology Clinic Oakville /ID# 277492
Oakville, Ontario
Canada

Contactez l'équipe d'étude

Eternal Springtime Dermatology /ID# 278598
Eternal Springtime Dermatology /ID# 278598
Thunder Bay, Ontario
Canada

Contactez l'équipe d'étude

Wiseman Dermatology Research /ID# 276847
Wiseman Dermatology Research /ID# 276847
Winnipeg, Manitoba
Canada

Contactez l'équipe d'étude

Factor Dermatology /ID# 278610
Factor Dermatology /ID# 278610
Ottawa, Ontario
Canada

Contactez l'équipe d'étude

Lovegrove Dermatology /ID# 276797
Lovegrove Dermatology /ID# 276797
London, Ontario
Canada

Contactez l'équipe d'étude

Centre for Medical and Surgical Dermatology /ID# 278775
Centre for Medical and Surgical Dermatology /ID# 278775
Whitby, Ontario
Canada

Contactez l'équipe d'étude

Étude parrainée par
AbbVie
Participants recherchés
Plus d'informations
ID de l'étude: NCT07039110